Could Apellis Pharmaceuticals Inc (NASDAQ:APLS) Change Direction After Less Shorts?

March 18, 2018 - By Adrian Mccoy

 Could Apellis Pharmaceuticals Inc (NASDAQ:APLS) Change Direction After Less Shorts?

The stock of Apellis Pharmaceuticals Inc (NASDAQ:APLS) registered a decrease of 2.1% in short interest. APLS’s total short interest was 1.17 million shares in March as published by FINRA. Its down 2.1% from 1.19 million shares, reported previously. With 88,500 shares average volume, it will take short sellers 13 days to cover their APLS’s short positions. The short interest to Apellis Pharmaceuticals Inc’s float is 4.97%.

The stock increased 5.99% or $1.47 during the last trading session, reaching $26.02. About 355,766 shares traded or 211.37% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.31 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.